Latest filings (excl ownership)
10-Q
2024 Q1
Quarterly report
8 May 24
8-K
Pfizer Reports First-Quarter 2024 Results
1 May 24
8-K
Submission of Matters to a Vote of Security Holders
29 Apr 24
PX14A6G
Letter to shareholders
16 Apr 24
DEFA14A
Additional proxy soliciting materials
11 Apr 24
DEFA14A
Additional proxy soliciting materials
11 Apr 24
DEFA14A
Additional proxy soliciting materials
11 Apr 24
DEFA14A
Additional proxy soliciting materials
9 Apr 24
DEFA14A
Additional proxy soliciting materials
28 Mar 24
DEFA14A
Additional proxy soliciting materials
28 Mar 24
ARS
2023 FY
Annual report to shareholders
14 Mar 24
DEFA14A
Additional proxy soliciting materials
14 Mar 24
DEF 14A
Definitive proxy
14 Mar 24
S-3ASR
Automatic shelf registration
23 Feb 24
S-8
Registration of securities for employees
23 Feb 24
10-K
2023 FY
Annual report
22 Feb 24
8-K
Pfizer Reports Full-Year 2023 Results and Reaffirms Full-Year 2024 Financial Guidance
30 Jan 24
8-K
Pfizer Recommends Shareholders Reject the Below-Market Mini-Tender Offer by TRC Capital Investment Corporation
10 Jan 24
8-K/A
Pfizer Completes Acquisition of Seagen
14 Dec 23
8-K
Pfizer Completes Acquisition of Seagen
14 Dec 23
8-K
Full-Year 2024 Revenue Guidance(1) Range of $58.5 to $61.5 Billion Includes Expected Contribution from Seagen Acquisition
13 Dec 23
8-K
Pfizer Receives All Required Regulatory Approvals to Complete the Acquisition of Seagen
12 Dec 23
10-Q
2023 Q3
Quarterly report
8 Nov 23
8-K
Pfizer Reports Third-Quarter 2023 Results
31 Oct 23
8-K
Pfizer Amends U.S. Government Paxlovid Supply Agreement and Updates Full-Year 2023 Guidance
13 Oct 23
10-Q
2023 Q2
Quarterly report
9 Aug 23
8-K
Pfizer Reports Second-Quarter 2023 Results
1 Aug 23
8-K
Departure of Directors or Certain Officers
27 Jul 23
8-K
Other Events
19 May 23
424B5
Prospectus supplement for primary offering
18 May 23
FWP
Free writing prospectus
16 May 23
424B3
Prospectus supplement
15 May 23
POSASR
Automatic shelf registration (post-effective amendment)
15 May 23
8-K
Other Events
15 May 23
10-Q
2023 Q1
Quarterly report
10 May 23
8-K
Pfizer Reports First-Quarter 2023 Results
2 May 23
8-K
Submission of Matters to a Vote of Security Holders
1 May 23
PX14A6G
Letter to shareholders
12 Apr 23
DEFA14A
Additional proxy soliciting materials
10 Apr 23
DEFA14A
Additional proxy soliciting materials
10 Apr 23
Latest ownership filings
4
JENNIFER B. DAMICO
1 May 24
4
ALBERT BOURLA
1 May 24
4
James Quincey
26 Apr 24
4
JAMES C SMITH
26 Apr 24
4
JOHNSON SUZANNE M NORA
26 Apr 24
4
SHANTANU NARAYEN
26 Apr 24
4
DAN R. LITTMAN
26 Apr 24
4
Susan Hockfield
26 Apr 24
4
HELEN HOBBS
26 Apr 24
4
Scott Gottlieb
26 Apr 24
4
Joseph Echevarria
26 Apr 24
4
Susan Desmond-Hellmann
26 Apr 24
4
RONALD E BLAYLOCK
26 Apr 24
4
JENNIFER B. DAMICO
16 Apr 24
4
ALBERT BOURLA
16 Apr 24
4
JENNIFER B. DAMICO
11 Apr 24
4
ALBERT BOURLA
11 Apr 24
4
JENNIFER B. DAMICO
1 Apr 24
4
ALBERT BOURLA
1 Apr 24
4
JAMES C SMITH
1 Apr 24
4
SHANTANU NARAYEN
1 Apr 24
4
James Quincey
1 Apr 24
4
Joseph Echevarria
1 Apr 24
SC 13D/A
Haleon plc
22 Mar 24
SC 13D/A
Haleon plc
19 Mar 24
4
JENNIFER B. DAMICO
18 Mar 24
4
ALBERT BOURLA
18 Mar 24
SC 13G/A
Tourmaline Bio, Inc.
15 Mar 24
4
ALBERT BOURLA
5 Mar 24
4
CHRISTOFFEL BOSHOFF
1 Mar 24
4
Mikael Dolsten
29 Feb 24
4
David M Denton
28 Feb 24
4
Lidia Fonseca
28 Feb 24
4
Michael McDermott
28 Feb 24
4
CHRISTOFFEL BOSHOFF
28 Feb 24
4
Mikael Dolsten
28 Feb 24
4
SALLY SUSMAN
28 Feb 24
4
AAMIR MALIK
28 Feb 24
4
ALBERT BOURLA
28 Feb 24
4
RADY A JOHNSON
28 Feb 24